Please assess the completion status of the following clinical trial:

Trial Title: A Safety Study of Galcanezumab in Participants With Migraine, With or Without Aura

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have a diagnosis of episodic or chronic migraine as defined by International Headache Society (IHS) International Classification of Headache Disorders (ICHD)-3 beta guidelines (1.1, 1.2 or 1.3) (ICHD-3 2013), with a history of migraine headaches of at least 1 year prior to screening, and migraine onset prior to age 50.~* Prior to baseline, a history of 4 or more migraine headache days per month on average for the past 3 months.~Exclusion Criteria:~* Are currently enrolled in or have participated within the last 30 days or within 5 half-lives (whichever is longer) in a clinical trial involving an investigational product.~* Current use or prior exposure to galcanezumab or another CGRP antibody.~* Known hypersensitivity to multiple drugs, monoclonal antibodies or other therapeutic proteins, or to galcanezumab.~* History of persistent daily headache, cluster headache or migraine subtypes including hemiplegic (sporadic or familial) migraine, ophthalmoplegic migraine, and migraine with brainstem aura (basilar-type migraine) defined by IHS ICHD-3 beta.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Galcanezumab 120 mg (Type: EXPERIMENTAL): Galcanezumab 240mg given as loading dose at first dosing visit followed by 120 mg given by subcutaneous (SC) injection once a month for up to 11 months by auto injector or pre-filled syringe.
- Galcanezumab 240 mg (Type: EXPERIMENTAL): Galcanezumab 240 mg given by SC injection once a month for up to 12 months by auto injector or pre-filled syringe.

Based on this trial design, predict the completion outcome and termination type (if applicable).